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Instead of nephroureterectomy with bladder cuff excision, nephron-sparing surgery can be considered in
selected patients with non-muscle invasive upper urinary tract urothelial carcinoma. The role of kidney-
sparing surgery has been established for the management of low-grade urothelial carcinoma. We report
a solitary kidney patient with high-grade renal pelvis urothelial carcinoma treated with nephron-sparing
surgery by ex vivo tumor excision and autotransplantation. The results of the surgery were excellent.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.1. Introduction
Nephroureterectomy with bladder cuff excision is still the gold
standard therapy for upper urinary tract urothelial carcinoma
(UUT-UC). However, for patients with anatomically or functionally
solitary kidneys, signiﬁcant renal insufﬁciency or bilateral UUT-
UCs, dialysis will be inevitable after operation. Several nephron-
sparing approaches have been advocated to prevent the patient
from becoming anephric. Here, we report a solitary kidney patient
with high-grade renal pelvis urothelial carcinoma treated with
nephron-sparing surgery by laparoscopic nephrectomy, ex vivo
tumor excision, and autotransplantation.
2. Case report
A 64-year-old female had received nephroureterectomy with
bladder cuff excision for the right renal pelvis UC (pT1N0M0, high-
grade) 6 years earlier. Gross hematuria occurred and urothelial
carcinomas of the left middle third of the ureter and renal pelvisrtment of Surgery, Taichung
Section 4, Taichung 40705,
blished by Elsevier Taiwan LLC. Opwere found. The pelvic tumor caused dilatation of the collecting
system. A decision was made to perform a nephron-sparing pro-
cedure. Laparoscopic nephrectomy was performed trans-
peritoneally with about a 5-cm segment of distal ureter preserved.
The kidney was taken out through a Gibson incision. On the bench,
we ﬂushed the kidney with cold HTK (histidineetryptophane
ketoglutarate) solution. A 4 cm  3 cm  3 cm papillary tumor at
the anterior aspect of the renal pelvis with a tumor stalk about
1 cm 0.4 cmwas found after pyelotomy (Fig.1A).Wedge resection
was done with a safety margin of approximately 5 mm, which was
conﬁrmed by frozen section (Fig. 1B and C). All the calyces and
proximal ureter were checked with ﬂexible ureteroscope (Fig. 1D).
Pyeloplasty was performed by continuous suture with 4e0 vicryl.
We resected themiddle third ureter around 7 cmwhere the UCwas
located. The tumor was 0.5 cm  0.5 cm  0.5 cm. Meanwhile, left
external iliac vessels were isolated and looped. The kidneywas then
transferred back through the Gibson incision, and blood supply was
restored by anastomosing to the external iliac vessels in an end-to-
side fashion. Finally, ureteroureterostomy was done with double J
stenting. The procedure time was as follows: laparoscopic neph-
roureterectomy 110 minutes, warm ischemic time 4 minutes, cold
ischemic time 90 minutes, and vessel anastomosis 45 minutes. We
removed the double J stent 44 days after the operation. The post-
operative course was uneventful.en access under CC BY-NC-ND license.
Fig. 1. (A) Urothelial carcinoma located at anterior renal pelvis with a narrow tumor base (white arrow). (B) The tumor was excised with the scissor. (C) Biopsy forceps was used to
sample the tumor base for frozen section. (D) Flexible ureteroscope was engaged in the collecting process to check for residual tumor.
L.-H. Huang et al. / Urological Science 25 (2014) 146e148 147The pathology reported a high-grade UC with invasion to the
lamina propria of the renal pelvis and carcinoma in situ in the
ureter. This patient was followed up by ﬂushing urine cytology as
well as ureteroscopy and retrograde pyelography alternatively
every 3 months in the ﬁrst 2 years and every 6 months thereafter
(Fig. 2). No tumor was noted 44 months after the procedure, and
the obstructive uropathywas relieved. The preoperative glomerular
ﬁltration rate was 22 mL/min, and 3 years after the operation was
76 mL/min.
3. Discussion
For the management of non-muscle-invasive UUT-UC with low-
grade status, the 5-year survival rate after local resection was
comparable to that after radical nephroureterectomy.1 However,
kidney-preserving operations are not suggested for high-gradeFig. 2. (A) Preoperative retrograde pyelography reveals ﬁlling defect in renal pelvis and d
recurrence in the upper urinary tract and relief of obstructive uropathy.tumors.2 In our case, nephroureterectomy would have necessi-
tated hemodialysis, which may cause complications and involve
signiﬁcant medical expenses. In one study, the cost savings ranged
from3-fold to 10-fold for a patient with UUT-UCwho received renal
preservation in comparison with patients in the hemodialysis
cohort.3 In addition, the quality of life becomes impaired once he-
modialysis has been commenced.4 In Taiwan, the 5-year survival
rate of patients with hemodialysis was 53.7%.5 To date, no evidence
has indicated that the overall survival rate of dialysis is better than
that after renal preserving procedures in patients with resectable
UUT-UC. Hence, for single-kidney patients with high-grade UUT-
UC, nephron-preserving procedures could be considered.
Several reports demonstrated pyelovesicostomy during renal
autotransplantation.6e8 It facilitates access to the collecting system
and allows further tumor resection or Bacillus CalmetteeGuérin
(BCG) instillation. Instead of pyelovesicostomy, ureteroureterostomyilated collecting system. (B) Postoperative retrograde pyelography showed no tumor
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least for the prevention of deterioration of renal function. In our pa-
tient, the glomerular ﬁltration rate improved from 22 mL/min (pre-
operation) to 76 mL/min (3 years after surgery). In addition, ureter-
oureterostomy offers a good and easy way for clinical follow-up,
including retrograde pyelography and ureteroscopy.
We did not perform BCG instillation although a high-grade tu-
mor had formed in this case. For UUT-UC, BCG instillation has its
own limitations. It has more severe side effects than when used
intravesically, and it is difﬁcult to achieve BCG retention in the
collecting system. In addition, there are no proven beneﬁts for
survival and recurrence rates.9
For the management of low-grade UUT-UC, the advantages of
nephroureterectomy were overestimated, whereas those of
nephron-sparing surgery were underestimated. Nephron-sparing
surgery is not suggested in the management of high-grade UUT-
UC.6,8,10 Holmäng and Johansson1 reported a series involving the
treatment of tumors with local resection and autotransplantation
after 20 years of follow-up. Tumor recurrence was not speciﬁcally
found in high-grade tumors, but was noted in low-grade tumors.
The authors concluded that tumor size, location, and number may
be important factors for tumor recurrence. In our case, the high-
grade tumor was easily handled because it was a single lesion
and narrow at the base. No local recurrence was noted during
regular follow-up.
In managing such a case, there are choices other than Bench
operation, including ureteroscopic or percutaneous nephroscopic
tumor ablation and open pyelotomy with tumor resection. The ure-
teroscopic or nephroscopic approach provides comparable outcomes
to nephroureterectomy in early-stage and low-grade tumors.11,12 In
high-grade tumors, the recurrence rate was as high as 60% after
ureteroscopic tumor ablation and 42% after nephroscopic pro-
cedures.13 Endoscopic approaches have several limitations, such as
limited working space, difﬁculty in determining the depth of tumor
invasion, problems controlling massive bleeding, and urinary tract
penetration. Percutaneous access was indicated for bulky intrarenal
tumors (>2 cm). Nevertheless, the complication rate of percutaneous
access (10e20%) is higher than thatof ureteroscopy (5e10%).14 Tumor
seeding of the percutaneous tract has been reported.15 As an alter-
native in these patients, pyelotomy with tumor excision is rarely
done. The recurrence ratewas as high as 65%, owing to tumor spillage
or incomplete tumor resection during the operation.16
Because there have been few randomized prospective studies,
the decision to perform nephron-sparing surgery in UUT-UC has to
be justiﬁed according to the patient’s individual situation. The
current consensus about preserving the kidney is limited to cases of
low-grade tumors. In high-grade tumors, the operation should only
be performed in selected patients, such as those with superﬁcial
lesions, solitary tumor, small tumor, and impending renal failure.
The patient should be informed about the high recurrence rate and
possible disease progression with UUT-UC.
In conclusion, we performed nephron-sparing surgery for a
patient with high-grade UTT-UC. The results were excellent interms of oncological control, preservation of renal function, lower
cost, and convalescence. In selected patients, laparoscopic ne-
phrectomy combined with ex vivo tumor excision and auto-
transplantation is a viable option, even in cases of high-grade
tumors.
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